176 related articles for article (PubMed ID: 37106214)
61. The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3967-3969. PubMed ID: 31262929
[TBL] [Abstract][Full Text] [Related]
62. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
63. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
[TBL] [Abstract][Full Text] [Related]
64. TAS-102 for the treatment of metastatic colorectal cancer.
Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
[TBL] [Abstract][Full Text] [Related]
65. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Yoshino T; Van Cutsem E; Li J; Shen L; Kim TW; Sriuranpong V; Xuereb L; Aubel P; Fougeray R; Cattan V; Amellal N; Ohtsu A; Mayer RJ
ESMO Open; 2022 Jun; 7(3):100511. PubMed ID: 35688062
[TBL] [Abstract][Full Text] [Related]
66. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
[TBL] [Abstract][Full Text] [Related]
67. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
Takahashi M; Sakamoto Y; Ohori H; Tsuji Y; Kuroki M; Kato S; Otsuka K; Komine K; Takahashi M; Takahashi S; Shirota H; Ouchi K; Takahashi Y; Imai H; Shibata H; Yoshioka T; Tanaka M; Yamaguchi H; Yamaguchi T; Shimodaira H; Ishioka C
Cancer Chemother Pharmacol; 2021 Sep; 88(3):393-402. PubMed ID: 34028598
[TBL] [Abstract][Full Text] [Related]
68. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K; Furuta M; Furusawa K; Hamaguchi T; Watanabe M; Inokuchi Y; Onuma S; Hashimoto I; Suematsu H; Nagasawa S; Kanematsu K; Yamada T; Notsu A; Ogata T; Oshima T; Machida N; Furuse J; Maeda S
Anticancer Res; 2023 Jun; 43(6):2831-2840. PubMed ID: 37247885
[TBL] [Abstract][Full Text] [Related]
69. Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Ding PQ; Dolley A; Cheung WY
Curr Oncol; 2022 Dec; 30(1):130-144. PubMed ID: 36661660
[TBL] [Abstract][Full Text] [Related]
70. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
[TBL] [Abstract][Full Text] [Related]
71. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey.
Özet A; Dane F; Aykan NF; Yalçın Ş; Evrensel T; Özkan M; Karabulut B; Ormeci MN; Atasev O; Vidot L; Çiçin İ
Future Oncol; 2022 Sep; 18(29):3267-3276. PubMed ID: 36040321
[No Abstract] [Full Text] [Related]
72. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani J
Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632
[TBL] [Abstract][Full Text] [Related]
73. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
[TBL] [Abstract][Full Text] [Related]
74. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
[TBL] [Abstract][Full Text] [Related]
75. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
[TBL] [Abstract][Full Text] [Related]
76. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C; Calegari MA; Basso M; Anghelone A; Lucchetti J; Minelli A; Angotti L; Zurlo IV; Schirripa M; Chilelli MG; Morelli C; Dell'Aquila E; Cosimati A; Gemma D; Ribelli M; Emiliani A; Corsi DC; Arrivi G; Mazzuca F; Zoratto F; Morandi MG; Santamaria F; Saltarelli R; Ruggeri EM
Curr Oncol; 2023 Jun; 30(6):5456-5469. PubMed ID: 37366896
[TBL] [Abstract][Full Text] [Related]
77. Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
Burness CB; Duggan ST
Drugs; 2016 Sep; 76(14):1393-402. PubMed ID: 27568360
[TBL] [Abstract][Full Text] [Related]
78. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
79. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
[TBL] [Abstract][Full Text] [Related]
80. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.
Van Cutsem E; Falcone A; Garcia-Carbonero R; Komatsu Y; Pastorino A; Peeters M; Shimada Y; Yamazaki K; Yoshino T; Zaniboni A; Amellal N; Kanehisa A; Winkler R; Makris L; Mayer RJ; Ohtsu A; Tabernero J
ESMO Open; 2017; 2(5):e000261. PubMed ID: 29215098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
